| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2000 | WO2000000468A1 Thyroid hormone analogues and methods for their preparation |
| 01/06/2000 | WO2000000465A1 Hydrazine derivatives |
| 01/06/2000 | WO2000000462A1 Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
| 01/06/2000 | WO2000000458A1 Substituted propionyl derivatives and intermediates thereof |
| 01/06/2000 | WO2000000238A1 Topoisomerase inhibitors for prevention of restenosis |
| 01/06/2000 | WO2000000220A1 Pharmaceutical composition containing an ester or amide pla2 inhibitor |
| 01/06/2000 | WO2000000212A1 Promoting nitric oxide and cyclic gmp activity |
| 01/06/2000 | WO2000000207A1 Treatment of hyperproliferative disorders |
| 01/06/2000 | WO2000000205A1 Inositolphosphoglycan and ribose for treatment of ischaemia-reperfusion injury |
| 01/06/2000 | WO2000000204A1 Indium photosensitizers for pdt |
| 01/06/2000 | WO2000000203A1 Azepine derivatives having effects on serotonin related systems |
| 01/06/2000 | WO2000000202A1 Method for inhibiting c-jun expression using jak-3 inhibitors |
| 01/06/2000 | WO2000000201A1 BICYCLIC sPLA2 INHIBITORS |
| 01/06/2000 | WO2000000200A1 A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR |
| 01/06/2000 | WO2000000199A1 Nasal delivery of sildenafil citrate |
| 01/06/2000 | WO2000000198A1 Piperidine derivatives having effects on serotonin related systems |
| 01/06/2000 | WO2000000197A1 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
| 01/06/2000 | WO2000000196A1 Pyrrolidine and pyrroline derivatives having effects on serotonin related systems |
| 01/06/2000 | WO2000000195A1 Pharmaceutical composition for the treatment of diabetes |
| 01/06/2000 | WO2000000194A1 Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| 01/06/2000 | WO2000000193A1 Methods and pharmaceutical formulations for preventing and treating motion sickness |
| 01/06/2000 | WO2000000192A1 INHIBITION OF NF-λB MEDIATED TISSUE INJURY USING DITHIOCARBAMATE DERIVATIVES |
| 01/06/2000 | WO2000000191A1 Use of cytoprotectants |
| 01/06/2000 | WO2000000190A1 Therapeutic agents |
| 01/06/2000 | WO2000000189A1 Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| 01/06/2000 | WO2000000188A2 Synthetically prepared hydroxy citric acid composition for the treatment and/or prophylaxis of overweight and use thereof |
| 01/06/2000 | WO2000000187A1 Medicinal compositions for treating evacuatory insufficiency |
| 01/06/2000 | WO2000000186A1 Method of treating topical ailments |
| 01/06/2000 | WO2000000185A1 Cloning and uses of the genetic locus bcl-6 |
| 01/06/2000 | WO2000000184A2 Use of histamine h2 mimicking substances for the treatment of multiple sclerosis |
| 01/06/2000 | WO2000000183A2 Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin |
| 01/06/2000 | WO2000000182A2 Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies |
| 01/06/2000 | WO2000000181A1 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| 01/06/2000 | WO2000000166A2 Improved oral compositions for control and prevention of tartar, oral malodor, plaque and gingivitis |
| 01/06/2000 | WO2000000161A2 Methods for identification of tef-3 interacting factors |
| 01/06/2000 | WO2000000158A2 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function |
| 01/06/2000 | WO2000000157A2 Use of tempo and tempo derivatives for inducing cell death |
| 01/06/2000 | WO2000000120A1 Methods and transdermal compositions for pain relief |
| 01/06/2000 | WO2000000039A1 Process and product for promoting weight loss in overweight dogs |
| 01/06/2000 | WO2000000023A1 Hydrophilic polymer blends used to prevent cow skin infections |
| 01/06/2000 | WO1999058505A3 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
| 01/06/2000 | WO1999057301A8 Compounds having glucuronic acid derivatives and glucosamine derivatives in the structure, process for producing the same and utilization thereof |
| 01/06/2000 | WO1999057136A3 Binding partner and method for the competitive inhibition of binding between nef protein and calmodulin, agent containing said binding partner and it use in hiv-related diseases |
| 01/06/2000 | WO1999055900A3 Gcp |
| 01/06/2000 | WO1999055855A3 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
| 01/06/2000 | WO1999052517A3 Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps |
| 01/06/2000 | WO1999048483A3 (-)-phenylpropanolamine as a sympathomimetic drug |
| 01/06/2000 | WO1999043661A3 Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands |
| 01/06/2000 | WO1999029310A3 Regulation of t cell-mediated immunity by tryptophan and its analogs |
| 01/06/2000 | WO1999017759A3 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
| 01/06/2000 | WO1998034942A3 Dinucleotides and their use |
| 01/06/2000 | CA2337999A1 Method for inhibiting c-jun expression using jak-3 inhibitors |
| 01/06/2000 | CA2336625A1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 01/06/2000 | CA2336309A1 Tubulin binding compounds (cobra) |
| 01/06/2000 | CA2336306A1 Indium photosensitizers for pdt |
| 01/06/2000 | CA2336294A1 Synthetic spiroketal pyranes as potent anti-cancer agents |
| 01/06/2000 | CA2336285A1 Aryl phosphate derivatives of d4t having anti-hiv activity |
| 01/06/2000 | CA2336254A1 5-ht1f agonists |
| 01/06/2000 | CA2336162A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them |
| 01/06/2000 | CA2336151A1 Pharmaceutical composition for the therapy of voiding dysfunction |
| 01/06/2000 | CA2336150A1 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands |
| 01/06/2000 | CA2336117A1 Piperidine derivatives having effects on serotonin related systems |
| 01/06/2000 | CA2336108A1 Alkyl ketones as potent anti-cancer agents |
| 01/06/2000 | CA2336089A1 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands |
| 01/06/2000 | CA2335986A1 Use of tempo and tempo derivatives for inducing cell death |
| 01/06/2000 | CA2335921A1 Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them |
| 01/06/2000 | CA2335846A1 Substituted benzopyran derivatives and their use as anticonvulsants |
| 01/06/2000 | CA2335842A1 Topoisomerase inhibitors for prevention of restenosis |
| 01/06/2000 | CA2335837A1 Methods and transdermal compositions for pain relief |
| 01/06/2000 | CA2335791A1 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function |
| 01/06/2000 | CA2335595A1 Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents |
| 01/06/2000 | CA2335523A1 Polyketides and their synthesis |
| 01/06/2000 | CA2335448A1 Bicyclic spla2 inhibitors |
| 01/06/2000 | CA2335310A1 Azepine derivatives having effects on serotonin related systems |
| 01/06/2000 | CA2335245A1 Hydrazine derivatives |
| 01/06/2000 | CA2334897A1 Pyrrolidine and pyrroline derivatives having effects on serotonin related systems |
| 01/06/2000 | CA2334686A1 Use of cytoprotectants |
| 01/06/2000 | CA2334515A1 A pharmaceutical combination comprising a cox-2 inhibitor and a inos inhibitor |
| 01/06/2000 | CA2334312A1 Therapeutic agents |
| 01/06/2000 | CA2332969A1 Materials and methods relating to the prevention or treatment of ischaemia-reperfusion injury |
| 01/06/2000 | CA2332121A1 Methods for inhibiting tef-3 activity |
| 01/06/2000 | CA2331399A1 Thienopyridine compounds, their production and use |
| 01/06/2000 | CA2330110A1 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors |
| 01/06/2000 | CA2327888A1 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
| 01/05/2000 | EP0969091A2 Leptin receptor gene-related protein |
| 01/05/2000 | EP0969017A1 Modified C1-esterase inhibitor for blocking infectivity of HIV |
| 01/05/2000 | EP0969005A1 Azabicyclic inhibitors of serotonin reuptake |
| 01/05/2000 | EP0968998A1 Cosmetic compositions, ceramide analogues with anti-elastase activity and process for their preparation |
| 01/05/2000 | EP0968719A2 Enzyme composition capable of forming an oligosaccharide in vivo |
| 01/05/2000 | EP0968717A1 Galenic formulatin for reducing effects induced during or after menopause and method of treatment using same |
| 01/05/2000 | EP0968716A1 Drugs for ameliorating ocular circulatory disorders |
| 01/05/2000 | EP0968715A1 Loratadine for use as an antiarrhymthmic |
| 01/05/2000 | EP0968714A1 Process to prepare fast dissolving pharmaceutical compositions containing hardly soluble agents |
| 01/05/2000 | EP0968713A1 Plasters containing isosorbide nitrate |
| 01/05/2000 | EP0968712A1 Felbinac-containing patch |
| 01/05/2000 | EP0968706A2 Formulations for controlling human lice containing spynosin |
| 01/05/2000 | EP0968432A1 Growth factor-dependent diseases |
| 01/05/2000 | EP0968293A1 Staphylococcus 3-dehydroquinate synthase |
| 01/05/2000 | EP0968226A1 G-rich oligo aptamers and methods of modulating an immune response |
| 01/05/2000 | EP0968225A1 NOVEL spsB |